Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2014 by Eisai Inc..
Recruitment status was  Active, not recruiting
PharmaBio Development Inc.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: April 28, 2011
Last updated: July 17, 2014
Last verified: July 2014
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2014
  Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)